论文部分内容阅读
目的了解Th17细胞因子IL-17A水平与乙肝疫苗免疫无/弱应答发生的关联。方法在1 481名完成乙肝疫苗全程接种的年轻成人中筛选出无/弱应答者30人,根据无/弱应答者性别、年龄和BMI,分别选择抗-HBs抗体中滴度、高滴度正常应答者各30例与之匹配形成对照,检测、比较三组人群血清中IL-17A的浓度差异。并检测无/弱应答者,加强接种1剂次60μg乙肝疫苗后血清IL-17A变化情况。结果 IL-17A在无/弱应答组血清水平中位数为225.16pg/ml(QIR:176.91,287.13),中滴度组为237.37pg/ml(QIR:164.09,266.68),高滴度组为219.05pg/ml(QIR:194.62,261.82),三组间差异无统计学意义(x~2=0.072,P=0.965);无/弱应答组在加强一剂次后IL-17A浓度为241.64pg/ml(QIR:222.40,241.64),高于加强前水平,但差异无统计学意义(Z=-1.175,P=0.240)。结论本研究未能证明Th17细胞因子IL-17A与乙肝疫苗接种无/弱反应发生存在关联。
Objective To understand the association of Th17 cytokine IL-17A level with the immune-naive / weak response of hepatitis B vaccine. Methods A total of 1 481 young adults who had been vaccinated with hepatitis B vaccine were enrolled in this study. Thirty non / weak responders were screened out. According to the gender, age and BMI of the non-responders, the titers and the high titers of anti-HBs were selected All 30 responders matched with each other to detect and compare the serum concentration of IL-17A in three groups. And detect no / weak responders, to strengthen the vaccination of a dose of 60μg hepatitis B vaccine serum IL-17A changes. Results The median serum level of IL-17A was 225.16 pg / ml (QIR: 176.91, 287.13) and 237.37 pg / ml (QIR: 164.09, 266.68) 219.05pg / ml (QIR: 194.62,261.82). There was no significant difference among the three groups (x ~ 2 = 0.072, P = 0.965). The concentration of IL-17A in the non-weak response group was 241.64pg /ml(QIR:222.40,241.64), higher than the level of pre-emptive, but the difference was not statistically significant (Z = -1.175, P = 0.240). Conclusion This study failed to demonstrate the association of Th17 cytokine IL-17A with no / weak response to hepatitis B vaccination.